E2100 — Paclitaxel With or Without Bevacizumab as First-Line Therapy for Metastatic Breast Cancer

Phase 3 · 2007 · Breast Cancer

Design

Randomized weekly paclitaxel with or without bevacizumab as first-line therapy.

Population

HER2-negative metastatic breast cancer.

Primary Endpoint

progression-free survival (PFS)

Key Result

PFS 11.8 vs 5.9 mo (HR 0.60) and higher response rate, without an overall survival benefit.

Guideline Impact

Breast cancer indication later withdrawn by the FDA; remains a reference case for PFS-based approvals